Incyte (LTS:0J9P) Other Current Payables : $0 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Incyte Other Current Payables?

Incyte's Other Current Payables for the quarter that ended in Mar. 2024 was $0 Mil.

Incyte's quarterly Other Current Payables declined from Sep. 2023 ($0 Mil) to Dec. 2023 ($-0 Mil) but then increased from Dec. 2023 ($-0 Mil) to Mar. 2024 ($0 Mil).

Incyte's annual Other Current Payables stayed the same from Dec. 2021 ($0 Mil) to Dec. 2022 ($0 Mil) but then declined from Dec. 2022 ($0 Mil) to Dec. 2023 ($-0 Mil).

Incyte Other Current Payables Historical Data

The historical data trend for Incyte's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Other Current Payables Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Payables

Get a 7-Day Free Trial

Incyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Payables	Get a 7-Day Free Trial															-	-	-	-	-

Incyte Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Incyte Other Current Payables Related Terms

Thank you for viewing the detailed overview of Incyte's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (LTS:0J9P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (LTS:0J9P) » Definitions » Other Current Payables

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (LTS:0J9P) Headlines

No Headlines